Randox Evidence Investigator used in major HIV/AIDS study

Home - Randox Evidence Investigator used in major HIV/AIDS study

The Department of Clinical Biochemistry in the Royal Free Hospital in London has recently completed a major HIV/AIDS study into the cause of lipodystrophy, with the help of the Randox Evidence Investigator.

Lipodystrophy is a disorder in which the body’s distribution of fat undergoes serious changes.  People with lipodystrophy can suffer from the build-up, the loss, or the redistribution of body fat and HIV/AIDS patients often suffer from the disorder.

The exact reason for its cause and progression is not completely understood, but it is thought that it can sometimes be triggered by an infection within the body.

The Department of Clinical Biochemistry in the Royal Free Hospital, alongside the Department of Pharmacology, The Institute of Biomedical Statistics and Infectious and Tropical Diseases, all at the University of Belgrade in Serbia, therefore launched a study to determine the relationship between levels of interleukins in HIV/AIDS patients and the presence or lack of lipodystrophy.  Interleukins are produced by white blood cells to stimulate the immune response.

The Randox Evidence Investigator, a semi-automated benchtop analyser, which is capable of processing up to 2376 tests per hour, was used to measure interleukins IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10, in 66 HIV/AIDS patients.  The results demonstrated that lower levels of IL-4 and IL-10 influenced lipodystrophy in those people.

Significantly lower levels of IL-4 and IL-10 were observed in patients suffering from lipodystrophy compared to those who did not suffer from lipodystrophy.  The interleukin levels were measured using the Cytokine Array I that utilises Randox’s Biochip Array Technology and enabled all of the tests to be performed simultaneously on the patient sample.

These results show for the first time a significant correlation between IL-4 levels and lipodystrophy in HIV/AIDS patients, making the study a significant breakthrough in understanding the development of the condition and potential therapy.

You can find more information about the study on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28189545

For more information on our Evidence Series range of Biochip immunoanalysers please visit www.randox.com/multiplex-testing or email EvidenceSeries@randox.com


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
  • This field is for validation purposes and should be left unchanged.
×
Kit Insert Request - Reagents
×
Kit Insert Request - Reagents
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Reagents
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Make an Enquiry
×
Make an Enquiry
×
Make an Enquiry
×